Cytokinetics (CYTK) CFO trims stake with 23,906-share sale

Rhea-AI Filing Summary

CYTOKINETICS INC executive Sung Lee, EVP and Chief Financial Officer, sold shares in an open-market transaction. On May 5, 2026, Lee sold 23,906 shares of Cytokinetics common stock at an average price of $76.87 per share. After this sale, Lee directly owned 63,221 common shares of the company.

Insider Trade Summary 10b5-1

Net Seller: 23,906 shares ($1,837,654)

Net Sell 1 txn

Insider Lee Sung

Role EVP, Chief Financial Officer

Sold 23,906 shs ($1.84M)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,906	$76.87	$1.84M

Holdings After Transaction: Common Stock — 63,221 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 23,906 shares Sale price per share: $76.87 per share Shares owned after sale: 63,221 shares +1 more

4 metrics

Shares sold 23,906 shares Open-market sale of common stock on May 5, 2026

Sale price per share $76.87 per share Average price for the May 5, 2026 sale

Shares owned after sale 63,221 shares Direct holdings following the reported transaction

Transaction code S Indicates open-market or private sale of non-derivative stock

Key Terms

open-market sale, non-derivative, transaction code S, direct ownership

4 terms

open-market sale financial

"transaction_action: "open-market sale" for the common stock transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type is listed as "non-derivative" for the common stock"

transaction code S financial

"transaction_code: "S" described as sale in open market or private transaction"

direct ownership financial

"direct_or_indirect set to "D" and ownership_type labeled as "direct""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Sung

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		S		23,906	D	$76.87	63,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Lee	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTOKINETICS (CYTK) report for Sung Lee?

CYTOKINETICS reported that EVP and Chief Financial Officer Sung Lee executed an open-market sale of company stock. On May 5, 2026, Lee sold 23,906 shares of Cytokinetics common stock at an average price of $76.87 per share.

How many CYTOKINETICS (CYTK) shares did Sung Lee sell and at what price?

Sung Lee sold 23,906 shares of CYTOKINETICS common stock in an open-market sale. The shares were sold at an average price of $76.87 per share, according to the Form 4 insider transaction report for May 5, 2026.

What is Sung Lee’s remaining CYTOKINETICS (CYTK) share ownership after this sale?

Following the May 5, 2026 transaction, EVP and Chief Financial Officer Sung Lee directly owned 63,221 shares of CYTOKINETICS common stock. This post-transaction holding reflects the number of shares reported as directly owned after the disclosed open-market sale.

Was the CYTOKINETICS (CYTK) insider trade by Sung Lee a buy or a sell?

The Form 4 filing shows that Sung Lee’s transaction was a sale. It is classified as an open-market sale of non-derivative common stock, identified with transaction code S and a transaction direction labeled as sell in the filing data.

What type of security did Sung Lee trade in the CYTOKINETICS (CYTK) Form 4?

The Form 4 indicates that Sung Lee traded Common Stock of CYTOKINETICS. The transaction was categorized as non-derivative, meaning it involved actual shares of common stock rather than options or other derivative securities, and it was executed as an open-market sale.